Saxenda (liraglutide) was one of the first GLP-1 receptor agonists specifically approved for weight management, and it remains a SAHPRA-registered, evidence-based option for South African patients. While newer medications like Ozempic and Mounjaro have largely taken centre stage, Saxenda continues to be prescribed — particularly for patients who have specific clinical reasons to prefer it. This guide covers everything you need to know.
At a glance: Saxenda is SAHPRA-registered for weight management in South Africa, injected daily, produces approximately 5–8% average body weight loss, and costs R2,000–R3,500 per month. It may suit patients who prefer a daily injection schedule, those who tolerate liraglutide well, or those for whom once-weekly options are not preferred.
Saxenda is the brand name for liraglutide 3 mg, a GLP-1 receptor agonist manufactured by Novo Nordisk. The same active ingredient (liraglutide) exists in a lower dose under the brand name Victoza — which is used for type 2 diabetes management. Saxenda's 3 mg dose is specifically formulated and registered for obesity treatment.
Saxenda works by mimicking GLP-1, a naturally occurring gut hormone that suppresses appetite, slows gastric emptying, and helps regulate blood sugar. The result is reduced hunger, earlier satiety, and meaningful weight loss over time when combined with a calorie-appropriate diet.
Saxenda is SAHPRA Registered in South Africa for the management of obesity in adults with:
Unlike Ozempic (which is registered for diabetes and used off-label for weight loss), Saxenda's primary registered indication is weight management. This means there is no off-label element — your prescription is for Saxenda's registered purpose.
Saxenda uses a gradual dose escalation schedule over 5 weeks to minimise side effects. The target dose is 3 mg per day:
| Week | Daily Dose | Notes |
|---|---|---|
| Week 1 | 0.6 mg daily | Starter dose — minimises initial GI side effects |
| Week 2 | 1.2 mg daily | First increase |
| Week 3 | 1.8 mg daily | Second increase |
| Week 4 | 2.4 mg daily | Third increase |
| Week 5 onwards | 3.0 mg daily | Maintenance dose — the full therapeutic dose |
If you do not tolerate a dose increase (nausea, vomiting), it is acceptable to remain at the previous dose for longer before stepping up. Discuss with your doctor if you find the escalation too fast.
In head-to-head data (SCALE trials for liraglutide vs STEP trials for semaglutide), Ozempic produces approximately double the weight loss of Saxenda at its respective maximum doses. Mounjaro produces even greater weight loss than Ozempic. For most patients seeking maximum weight loss outcomes, Ozempic or Mounjaro is generally preferred.
However, Saxenda remains a valid option in specific circumstances — see below.
| Feature | Saxenda (Liraglutide) | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|---|
| Injection frequency | Once daily | Once weekly | Once weekly |
| Average weight loss | ~5–8% | ~12–15% | ~20–22% |
| SAHPRA registration (weight) | Registered | Off-label | Registered |
| SA monthly cost | R2,000 – R3,500 | R1,500 – R2,800 | R2,500 – R4,500 |
| Years on market | Longest track record | Established | Newer |
| Main mechanism | GLP-1 only | GLP-1 only | GLP-1 + GIP (dual) |
Despite lower average weight loss vs newer alternatives, Saxenda may be preferred when:
Saxenda's side effect profile is similar to other GLP-1 medications — predominantly gastrointestinal, most prominent during dose escalation, and improving over time for most patients:
Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical (animal study) thyroid tumour signal. The same contraindications apply as for other GLP-1 medications: history of MTC, MEN2, pancreatitis, severe GI disorders, pregnancy, and breastfeeding.
Saxenda comes in pre-filled, multi-dose injection pens. Each pen delivers a set number of doses at the dial-up dose you choose. Key points:
Take our free 2-minute quiz to get a personalised assessment — including which GLP-1 option may suit your profile best.
Take the Free Quiz →